379 related articles for article (PubMed ID: 27538846)
1. IMRT for head and neck cancer: reducing xerostomia and dysphagia.
Wang X; Eisbruch A
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i69-i75. PubMed ID: 27538846
[TBL] [Abstract][Full Text] [Related]
2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
3. Late dysphagia after IMRT for head and neck cancer and correlation with dose-volume parameters.
Mortensen HR; Jensen K; Aksglæde K; Behrens M; Grau C
Radiother Oncol; 2013 Jun; 107(3):288-94. PubMed ID: 23791365
[TBL] [Abstract][Full Text] [Related]
4. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
[TBL] [Abstract][Full Text] [Related]
5. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
Eisbruch A; Kim HM; Terrell JE; Marsh LH; Dawson LA; Ship JA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):695-704. PubMed ID: 11395238
[TBL] [Abstract][Full Text] [Related]
6. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.
Hunter KU; Schipper M; Feng FY; Lyden T; Haxer M; Murdoch-Kinch CA; Cornwall B; Lee CS; Chepeha DB; Eisbruch A
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):935-40. PubMed ID: 23040224
[TBL] [Abstract][Full Text] [Related]
7. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer.
Batth SS; Caudell JJ; Chen AM
Head Neck; 2014 Feb; 36(2):291-8. PubMed ID: 23508721
[TBL] [Abstract][Full Text] [Related]
9. Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer.
Anand AK; Chaudhoory AR; Shukla A; Negi PS; Sinha SN; Babu AA; Munjal RK; Dewan AK; Kumar K; Doval DC; Vaid AK
Br J Radiol; 2008 Nov; 81(971):865-71. PubMed ID: 18941046
[TBL] [Abstract][Full Text] [Related]
10. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
[TBL] [Abstract][Full Text] [Related]
11. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
12. Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.
Mazzola R; Ferrera G; Alongi F; Mannino M; Abbate B; Cucchiara T; Iacoviello G; Sciumè F; Di Paola G; Federico M; Blasi L; Lo Casto A; Lagalla R; Messana D
Radiol Med; 2015 Aug; 120(8):753-8. PubMed ID: 25663551
[TBL] [Abstract][Full Text] [Related]
13. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy: is xerostomia still prevalent?
Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
[TBL] [Abstract][Full Text] [Related]
15. [Research advances in prevention of radiation induced xerostomia by intensity-modulated radiation therapy].
Yan C; Wang ZH
Shanghai Kou Qiang Yi Xue; 2008 Oct; 17(5):540-4. PubMed ID: 18989600
[TBL] [Abstract][Full Text] [Related]
16. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.
Zhou J; Wang L; Qiu T; Gao H; Wang L; Huang S; He X; Wu L
BMC Cancer; 2024 May; 24(1):648. PubMed ID: 38802747
[TBL] [Abstract][Full Text] [Related]
18. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based organ-sparing radiotherapy in head and neck cancer.
Dirix P; Nuyts S
Lancet Oncol; 2010 Jan; 11(1):85-91. PubMed ID: 20129131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
